We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Genta has updated results from the company's Phase III trial of Genasense (oblimersen
sodium) injection in patients with relapsed or refractory chronic lymphocytic
leukemia.
Aphton has released final data from a double-blind, placebo-controlled Phase
III clinical trial of Insegia (G17DT immunogen) in combination with Gemzar (gemcitabine;
Lilly) in patients with solid tumors.
CuraGen has announced that TopoTarget A/S signed a cooperative research and
development agreement (CRADA) with the Division of Cancer Treatment and Diagnosis
(DCTD) at the National Cancer Institute (NCI) relating to PXD101, a histone
deacetylase (HDAC) inhibitor.
OncoGenex Technologies announced that results from a second Phase I study of
OGX-011, the company's lead product candidate, will be presented at the 41st
Annual Meeting of the American Society of Clinical Oncology (ASCO).
Vertex Pharmaceuticals has announced interim results that indicate that the
investigational oral hepatitis C virus (HCV) protease inhibitor VX-950 was well-tolerated
and demonstrated potent antiviral activity in a Phase Ib clinical trial.
Hana Biosciences has initiated a Phase I/II clinical study of talotrexin (PT-523)
as a single agent in adult patients with relapsed or refractory acute lymphoblastic
leukemia (ALL).
Samaritan Pharmaceuticals has officially initiated a Phase II double-blind,
placebo-controlled, multidose, monotherapy study in treatment-experience HIV
patients.